On March 14, 2023 Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, reported the company will present a poster presentation at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place April 14-19, 2023, in Orlando, Florida (Press release, Erasca, MAR 14, 2023, View Source [SID1234639360]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The abstract will be available on the AACR (Free AACR Whitepaper) meeting website. The poster will be available online at Erasca.com/science/presentations following the presentation.
Poster Presentation Details
Abstract CT184 – Preliminary dose escalation results of ERAS-601 in combination with cetuximab in FLAGSHP-1: A Phase 1 study of ERAS-601, a potent and selective SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors
Date/Time: Tuesday, April 18, 2023, 9:00 AM – 12:30 PM ET
Session: First-in-Human Phase I Clinical Trials 2
Presenter: Dr. Meredith McKean, Sarah Cannon Research Institute at Tennessee Oncology
Location: Orange County Convention Center, Poster Section 45, Poster Board 16